Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 1516374 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Ask a Question
Printer Friendly
PDF Brochure
Hard CopyAdd to Basket
Live Chat Live Help Software for Website

Acceptability of HIV Testing among Tuberculosis Patientsin Addis Ababa. Edition No. 1

VDM Publishing House, Sep 2009, Pages: 56


  Description  
   Authors   
    
    
    
     
  Enquire before Buying   
  Send to a Friend   

This study was conducted in March 2007 to assess acceptability of PIHCT and the factors influencing its uptake among TB patients in Addis Ababa. Institution-based, cross-sectional study was conducted and 423 TB patients interviewed. Most of the patients were initiated for HIV testing by their TB treatment supervisor 402(98.5%). Among those who were initiated by their treatment supervisor for HIV testing, 266(66.2%; 95%CI= 61.6-70.8) had under gone HIV testing. Adjusted correlates of acceptability of PIHCT include younger age group (20-24) (AOR=3.0, 95% CI=1.2-8.1), primary education (AOR=2.0, 95% CI=1.04-3.8), secondary and above education (AOR=1.9, 95% CI=1.01-3.7), and recognition that any one should get tested for HIV (AOR=5.5, 95% CI=1.4-21.7). The reported barriers for acceptability of PIHCT include no risk perception for HIV infection 54(40.3%), tested before 53(39.3%), and fear of learning positive result 40 (29.8%) of the study participants. The wide spread support, and evidence of high acceptability of PIHCT in this study holds significant promise for the control, prevention and treatment of both HIV/AIDS and TB



For enquiries please call us on:
  +353-1-415-1241 (GMT Office Hours)
  1-917-300-0470 (EST Office Hours)

   All rights reserved. © Copyright 2012 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network


Research and Markets RSS Feeds